Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Onxeo SA (C4X) - Total Liabilities
Latest total liabilities as of December 2024: €26.19 Million EUR
Based on the latest financial reports, Onxeo SA (C4X) has total liabilities worth €26.19 Million EUR as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Onxeo SA - Total Liabilities Trend (2013–2024)
This chart illustrates how Onxeo SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Onxeo SA Competitors by Total Liabilities
The table below lists competitors of Onxeo SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daemyoung Energy Co Ltd
KQ:389260
|
Korea | ₩235.98 Billion |
|
Socar Inc.
KO:403550
|
Korea | ₩458.63 Billion |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
USA | $285.91 Million |
|
Mi Chang Oil
KO:003650
|
Korea | ₩54.57 Billion |
|
Fynske Bank A/S
CO:FYNBK
|
Denmark | Dkr8.55 Billion |
|
Avantium Holding BV
AS:AVTX
|
Netherlands | €215.84 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Onxeo SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Onxeo SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Onxeo SA (2013–2024)
The table below shows the annual total liabilities of Onxeo SA from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €26.19 Million | +27.97% |
| 2023-12-31 | €20.47 Million | -1.67% |
| 2022-12-31 | €20.82 Million | +3.45% |
| 2021-12-31 | €20.12 Million | +15.17% |
| 2020-12-31 | €17.47 Million | -14.50% |
| 2019-12-31 | €20.43 Million | +14.48% |
| 2018-12-31 | €17.85 Million | -36.71% |
| 2017-12-31 | €28.20 Million | -9.07% |
| 2016-12-31 | €31.01 Million | +17.30% |
| 2015-12-31 | €26.44 Million | -11.96% |
| 2014-12-31 | €30.03 Million | +205.04% |
| 2013-12-31 | €9.84 Million | -- |